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ABSTRACT 28 
BACKGROUND: We have previously demonstrated that polyfunctional Ty21a-responsive CD4+ and 29 
CD8+ T cells are generated at the duodenal mucosa 18 days following vaccination with live-attenuated 30 
S. Typhi (Ty21a). The longevity of cellular responses has been measured in peripheral blood, but 31 
persistence of duodenal responses is unknown.  32 
METHODS: We vaccinated eight healthy adults with Ty21a. Peripheral blood and duodenal samples 33 
were acquired after a median of 1.5 years (ranging from 1.1 to 3.7 years) following vaccination. Cellular 34 
responses were assessed in peripheral blood and at the duodenal mucosa by flow cytometry. Levels 35 
of IgG and IgA were also assessed in peripheral blood by enzyme-linked immunosorbent assay.  36 
RESULTS: No T-cell responses were observed at the duodenal mucosa, but CD4+ T-cell responses to 37 
Ty21a and FliC were observed in peripheral blood. Peripheral anti-lipopolysaccharide IgG and IgA 38 
responses were also observed. Early immunoglobulin responses were not associated with the 39 
persistence of long- term cellular immune responses.  40 
CONCLUSIONS: Early T-cell responses which we have previously observed at the duodenal mucosa 18 41 
days following oral vaccination with Ty21a could not be detected at a median of 1.5 years. Peripheral 42 
responses were observed at this time. Immunoglobulin responses observed shortly after vaccination 43 
were not associated with cellular immune responses at 1.5 years, suggesting that the persistence of 44 
cellular immunity is not associated with the strength of the initial humoral response to vaccination.  45 
  46 
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INTRODUCTION 47 
Salmonella enterica serovar Typhi (S. Typhi) is a facultative intracellular pathogen and the causative 48 
agent of typhoid fever. This bacterium, which is restricted to its human host, is spread via the faecal-49 
oral route, and causes systemic illness following invasion via the mucosal surface of the small intestine 50 
[1]. A live-attenuated oral vaccine, designated Ty21a, was developed in the 1970s [2]. Vaccination with 51 
three doses of Ty21a is moderately protective, with a calculated cumulative efficacy of 48% between 52 
two and half and three years following vaccination [3]. It is estimated that 58% of all cases of disease 53 
in endemic regions occur in children under 5 years [4]. Although Ty21a has not been routinely 54 
administered in children, it has been demonstrated that when administered in liquid suspension, 55 
Ty21a is immunogenic in children aged between 2 and 6 years [5, 6]. 56 
Ty21a is able to induce humoral and cellular immune responses, both of which have been implicated 57 
in protection against disease. [7]The peripheral humoral response to Ty21a has not previously been 58 
assessed beyond 42 days [8]; however, one novel live-attenuated oral vaccine candidate, CVD 909, 59 
has demonstrated the capacity to generate memory B cells which persist for at least one year [9]. 60 
Peripheral cellular responses targeting soluble S. Typhi flagella (FliC) as well as infected host cells have 61 
been assessed following vaccination with Ty21a, and data indicate that T cells responding to these 62 
antigens can persist for at least two years post-vaccination [10-12].  63 
Recently, controlled human infection has demonstrated that polyfunctional CD8+ T cells are associated 64 
with protection against disease when volunteers are challenged with approximately 103 CFU [13], but 65 
are associated with an increased susceptibility to disease when volunteers are challenged with 66 
approximately 104 CFU [14]. It has been suggested that higher dose inoculum generates stronger 67 
inflammatory responses than the lower dose inoculum and that exposure to this inflammatory 68 
environment may favour systemic dissemination [14]. Thus, polyfunctional CD8+ T cells do appear to 69 
play a dominant role in protection against typhoid fever in humans. We have previously demonstrated 70 
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that vaccination with Ty21a generates robust, polyfunctional CD4+ and CD8+ T-cell responses at the 71 
duodenal mucosa and in peripheral blood at day 18 [7]; however, whether early duodenal responses 72 
persist in the long-term has yet to be determined. 73 
An increased understanding of the longevity of immune responses both at the intestinal mucosa and 74 
in peripheral blood may allow us to identify both early and late functional correlates of vaccine-75 
mediated protection, which are currently unknown. Here, we have assessed cellular immunity in 76 
orally-vaccinated volunteers at the duodenal mucosa and in peripheral blood after approximately 1.5 77 
years, and compared responses with those observed in a control group. We have compared and 78 
correlated peripheral and mucosal cellular responses with peripheral levels of anti-LPS IgG and IgA, an 79 
accepted correlate of vaccine efficacy, providing a unique insight into the longevity of human mucosal 80 
and peripheral immune defence.   81 
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MATERIALS AND METHODS 82 
Ethical approval, recruitment, and study protocol 83 
All volunteers provided written informed consent. This study was approved by the United Kingdom 84 
National Research Ethics Service (13/NW/0282). Eighteen healthy adult volunteers were enrolled into 85 
the study. Ten volunteers (5 males and 5 females; median age 24 years) were recruited to an 86 
unvaccinated control group. Eight volunteers (3 males and 5 females; median age 23.5 years) who had 87 
previously been vaccinated with live-attenuated S. Typhi (Ty21a; Vivotif®) as part of a previous study 88 
(10/H1005/20) were recalled (Table 1). Volunteers were not revaccinated during this study. During 89 
the previous study, volunteers were vaccinated with live-attenuated S. Typhi (Ty21a; Vivotif®), 90 
according to the manufacturer’s instructions – a single oral capsule was taken on days 0, 2 and 4, 91 
approximately 1 hour before a meal with a cold or lukewarm drink. Since we wished to assess the 92 
longevity of responses generated from the original vaccination, recalled volunteers were not 93 
revaccinated. Full details of the previous study (10/H1005/20) are presented in the Supplementary 94 
Materials and Methods.  95 
Mucosal mononuclear cell (MMC) isolation 96 
Mucosal samples were acquired approximately 1.5 years following vaccination. O2 was administered 97 
nasally, and saturation was monitored throughout endoscopic biopsy. Sedation was offered to all 98 
volunteers; those who re- quested sedation were given up to 5 mg of midazolam intravenously. By 99 
use of large-capacity forceps (Boston Scientific), 12-15 single-bite mucosal biopsy specimens were 100 
acquired during flexible video-endoscopy from the duodenal mucosa at parts D2-D3 (n = 16) MMCs 101 
were isolated from biopsy specimens, using a modified version of a previously described method.[15] 102 
Full details are presented in the Supplementary Materials and Methods. 103 
Peripheral blood mononuclear cell (PBMC) isolation 104 
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Peripheral blood samples were collected in lithium heparin Vacutainers (BD Biosciences) (n = 17) 6 105 
days prior to mucosal sampling. PBMCs were isolated using Histopaque-1077™ (Sigma-Aldrich), 106 
according to the manufacturer’s instructions. Full details are presented in the Supplementary 107 
Materials and Methods. 108 
Antigenic stimulation and incubation 109 
PBMCs (1 × 106 cells/well) and MMCs (approximately 1 × 106 cells/well) were seeded in complete 110 
medium in 96 well v-bottom plates. Cells in each well were stimulated with either 5 × 106 colony 111 
forming units (CFU) heat-killed Salmonella Typhi Ty21a (Vivotif; suspended in Dulbecco’s PBS, 112 
quantified using the Miles and Misra technique, and killed by incubation at 95˚C for 30 minutes) or 10 113 
ng FliC protein flagella. One positive control well was stimulated with 100 ng staphylococcal 114 
enterotoxin B (SEB; Sigma-Aldrich). One negative control well was left untreated to adjust for non-115 
antigen-specific background cytokine production. Cells were then incubated at 37°C in 5% CO2. After 116 
2 hours, 1 µL brefeldin A (BD GolgiPlug; BD Biosciences) and 1 µL monensin (BD GolgiStop; BD 117 
Biosciences) was added to each well, and the plate incubated for a further 16 hours at 37°C in 5% CO2. 118 
Flow cytometric analyses 119 
Following incubation, PBMCs and MMCs were washed, stained for viability and surface phenotype 120 
and, following fixation and permeabilisation, stained for intracellular cytokine production. Details of 121 
the antibodies that were used are presented in the Supplementary Materials and Methods. Cells were 122 
washed, resuspended and stored in the absence of light at 4°C until data were acquired using a LSR II 123 
flow cytometer (BD Biosciences). Compensation beads (BD Biosciences) were used to create 124 
compensation matrices and sequential cell isolation used to identify populations of interest (Figure 2). 125 
Full details are presented in the Supplementary Materials and Methods. 126 
Enzyme-linked immunosorbent assay (ELISA) 127 
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Each well in flat-bottomed 96-well microtitre plates (Nunc) was coated with 100 µL carbonate-128 
bicarbonate buffer containing either 50 ng S. typhi lipopolysaccharide (LPS; Sigma-Aldrich) and 129 
incubated at 4°C overnight. Plates were washed 3 times with PBS-Tween. Plates were blocked with 130 
1.0% bovine serum albumin and incubated for 2 hours at room temperature. A standard was created 131 
using serum obtained from a convalescent patient with a diagnosis of typhoid. Volunteer samples 132 
were diluted 4 times across an optimised range for optimum comparison against the standard. Plates 133 
were washed, samples were added in duplicate and incubated at 4˚C overnight. For detection of 134 
immunoglobulin G (IgG), plates were washed and incubated with 1:4,000 anti-human IgG-alkaline 135 
phosphatase (Sigma-Aldrich) for 2 hours. For detection of immunoglobulin A (IgA), plates were washed 136 
and incubated with 1:4,000 anti-human-IgA (AbD Serotec) for two hours; plates were washed again 137 
and then incubated with 1:2,000 streptavidin to alkaline phosphotase (AbD Serotec) for 1 hour. For 138 
detection of both IgG and IgA, plates were washed and incubated with 100µL p-nitrophenyl phosphate 139 
(Sigma-Aldrich). Optical density was measured at 405 nm using a FLUOstar Omega ELISA plate reader 140 
(BMG Labtech). 141 
Statistical analyses  142 
Comparisons were made using paired and unpaired t tests based on 1,000 bootstrapped samples, as 143 
indicated. Associations were measured using Pearson’s correlation coefficient. Statistical analyses 144 
were performed using SPSS v22 (IBM). Differences were considered significantly different if 145 
bootstrapped confidence intervals did not cross zero.   146 
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RESULTS 147 
Recruitment and sampling 148 
Eight volunteers who had previously been vaccinated as part of past studies were recalled for 149 
sampling. The period between vaccination and sampling varied, with the median period between 150 
vaccination and sampling at 1.5 years (Table 1; range from 1.1 to 3.7 years).  151 
Serum immunoglobulin specificity 152 
Ty21a-mediated protection is dependent upon the expression of LPS [2]. Although humoral responses 153 
to LPS are not believed to confer protection at an individual level, in field trials, they have been shown 154 
to correlate with overall vaccine efficacy and are useful measures of immunogenicity [16-18]. We 155 
measured levels of serum anti-LPS IgG and IgA in vaccinated volunteers and controls.  156 
At day 0 (baseline), levels of anti-LPS IgG and IgA did not differ between vaccinated and unvaccinated 157 
volunteers (Figure 1). Among vaccinated volunteers, levels of anti-LPS serum IgG were 6-fold higher 158 
at day 11 (T1), 5-fold higher at day 18 (T2) and 2-fold higher at approximately 1.5 years (T3) 159 
([bootstrapped 95% confidence interval (CI) based on arbitrary units (AU)]: -54874 to -7404, -44577 160 
to -5922 and -8911 to -317, respectively; Figure 1) than at baseline (T0).  161 
Similarly, among vaccinated volunteers, levels of anti-LPS serum IgA were 3-fold higher among 162 
vaccinated volunteers at day 11 and 2-fold at day 18 (-97104 to -27173 and -41746 to -12843, 163 
respectively; Figure 1) than at baseline. Levels of anti-LPS serum IgA at approximately 1.5 years were 164 
comparable with baseline. 165 
Peripheral blood and gut mucosal cellular responses 166 
We compared the frequency of Ty21a-responsive and FliC-responsive T cells in vaccinated volunteers 167 
and controls, at the duodenal mucosa and in peripheral blood. A combinatorial gating strategy was 168 
used to identify antigen-responsive cell populations; these were defined as the proportion of CD4+ 169 
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and CD8+ T cells positive for any combination of IFN-γ ± TNF-α ± IL-2 ± IL-17A ± MIP-1β following re-170 
stimulation (Figure 2). Cytokine production in non-stimulated samples (negative control) was minimal, 171 
did not differ between vaccinated and unvaccinated volunteers and was subsequently subtracted 172 
from other conditions. Cytokine production in SEB-stimulated samples (positive control) was high and 173 
did not differ between vaccinated and unvaccinated volunteers. 174 
Approximately 1.5 years following vaccination, at the duodenal mucosa, the frequencies of Ty21a-175 
responsive and FliC-responsive CD4+ and CD8+ T cells in the vaccinated group was not different from 176 
the unvaccinated control group (Figure 3A).  177 
Since overnight fasting, required prior to endoscopy, is known to influence cytokine production in 178 
peripheral blood in response to re-stimulation with bacterial antigens [19], we acquired non-fasting 179 
peripheral blood samples six days prior to gastroscopy. In peripheral blood, the frequency of Ty21a-180 
responsive CD4+ and CD8+ T cells was not significantly higher in the vaccinated group at a median of 181 
1.5 years, compared to the unvaccinated control group (Figure 3B). The frequency of FliC-responsive 182 
CD4+ T cells was 6-fold higher and CD8+ T cells 2-fold higher in the vaccinated group at a median of 1.5 183 
years, compared with the unvaccinated control group (([bootstrapped 95% CI based on percentage 184 
positive for combination of cytokine]: -3.48161 to -0.05863 and -5.46152 to -0.22464, respectively; 185 
Figure 3B). 186 
Characteristics and functionality of cellular responses  187 
Polyfunctional T cells, defined as cells that express multiple cytokines/chemokines simultaneously, 188 
have been shown to correlate with vaccine-mediated protection against other intracellular infections 189 
[20, 21]. After comparing the proportions of antigen-responsive populations, we assessed the cytokine 190 
expression profile of vaccinated volunteers with that of unvaccinated volunteers. Specifically, we 191 
assessed the functionality of the response as well as individual cytokine/chemokine production.  192 
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Consistent with our published data [7], responses among CD8+ T cells comprised far fewer 193 
polyfunctional subpopulations, both at the duodenal mucosa and in peripheral blood (Supplementary 194 
Figure 1 and Figure 4). Of the cytokines/chemokines studied here, MIP1β was consistently the most 195 
commonly expressed among Ty21a-responsive and FliC-responsive CD4+ and CD8+ T-cell populations, 196 
at the duodenal mucosa and in peripheral blood (Supplementary Figure 2 and Figure 5).  197 
At the duodenal mucosa, the frequencies of Ty21a-responsive or FliC-responsive CD4+ and CD8+ T cells 198 
expressing one, two, three, four or five cytokines/chemokines in the vaccinated group was not 199 
different from the unvaccinated control group (Supplementary Figure 1). Of the cytokines studied 200 
here, no discernible difference was observed between groups at the duodenal mucosa among either 201 
CD4+ and CD8+ T cells (Supplementary Figure 1). 202 
In peripheral blood, the frequency of polyfunctional Ty21a-responsive CD4+ T cells expressing four and 203 
five cytokines/chemokines was significantly higher in vaccinated volunteers than controls (-0.04385 204 
to -0.00047 and -0.00810 to -0.00016, respectively; Figure 4). Consistent with the polyfunctional 205 
nature of these responses, the frequency of IFN-γ, TNF-α, IL-2, IL17 and MIP-1β expression among 206 
Ty21a-responsive CD4+ T cells was increased (Figure 5). This suggests that the increased frequency of 207 
polyfunctional Ty21a-responsive CD4+ T cells generated in response to vaccination persists for at least 208 
1.5 years. 209 
The frequency of FliC-responsive CD4+ T cells expressing one and two cytokines/chemokines was 210 
higher in vaccinated volunteers than controls (-3.1896 to -0.52607 and -0.03688 to -0.00417, 211 
respectively; Figure 4). Analysis by individual cytokine revealed that the frequency of IFN-γ, TNF-α, IL-212 
2, and MIP-1β expression among FliC-responsive CD4+ T cells was increased (Figure 5).213 
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DISCUSSION 214 
We have previously described the early mucosal response to live oral vaccination with Ty21a in 215 
peripheral blood and at the human duodenal mucosa; here we assessed the long-term cellular 216 
response to Ty21a at the same site and compared duodenal responses with peripheral responses. We 217 
demonstrate that, while peripheral polyfunctional cellular responses persist for at least 1.5 years, 218 
duodenal responses – which we have previously observed at day 18 [7] – do not persist. The strength 219 
of early peripheral humoral responses to S. Typhi LPS, which have previously been associated with 220 
protective efficacy [18], were not associated with the strength of peripheral cellular responses at 221 
approximately 1.5 years. 222 
In contrast with observations made at 18 days [7], no response was observed at the duodenal mucosa 223 
in either T-cell subset approximately 1.5 years following vaccination. Peripheral polyfunctional T-cell 224 
responses did persist and could be detected at 1.5 years. This suggests that local duodenal responses 225 
are more transient than peripheral responses. 226 
For some time the generation of polyfunctional T cells has been believed to be an important factor in 227 
conferring protection against typhoid fever [12, 13, 22, 23]. Recently it has been demonstrated that, 228 
when volunteers are challenged with 103 CFU, polyfunctional CD8+ T cells are associated with 229 
protection against typhoid fever [13]. Consistent with our previously published data [7], the frequency 230 
of responsive cells tended to be higher amongst CD4+ T cells; this is likely due to our use of soluble 231 
antigen preparations, which are dependent upon cross-presentation to engage cytotoxic CD8+ T cells 232 
[24-26]. Interestingly, while Ty21a-responsive CD4+ T cells comprised subsets which simultaneously 233 
expressed four and five cytokine/chemokines, FliC-responsive CD4+ T cells tended to express just one 234 
or two cytokines/chemokines. This suggests that the FliC antigen alone is not responsible for the 235 
generation of polyfunctional responses and that other antigens, which are present in the heat-killed 236 
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Ty21a preparation, are responsible for the induction of polyfunctional responses, which are more 237 
likely to play a role in protection against disease.  238 
The fact that duodenal responses are transient, may indicate that the composition of mucosal T-cell 239 
populations is subject to considerable change. This may be due to the relatively high frequency with 240 
which different pathogens are encountered at the intestinal mucosa, and rapid changes in the 241 
regulation of mucosal homing ligands. It has previously been demonstrated that peripheral responses, 242 
generated through vaccination with Ty21a, with increased mucosal homing potential, persist in 243 
peripheral circulation for at least 90 days [25]. Thus, if S. Typhi were to be re-encountered at the 244 
intestinal mucosa, long-lived peripheral cell populations would likely possess an enhanced capacity to 245 
rapidly migrate to the mucosal surface through innate signalling and homing receptor up regulation 246 
[27]. 247 
Consistent with our previously published observations [7], all volunteers had detectable baseline 248 
levels of serum immunoglobulin specific to S. Typhi LPS. This may be the result of immunoglobulin 249 
binding to the core, or as a result of environmental exposure to non-typhoidal strains bearing the 250 
same LPS O-antigens as S. Typhi (O-9 and O-12) [28]. Not all vaccinated volunteers generated 251 
peripheral humoral anti-LPS responses; likely a reflection of the known limited efficacy of this vaccine 252 
[3]. While levels of serum anti-LPS IgG were significantly higher across all 3 time points, the strength 253 
of early responses steadily declined. Similarly, early anti-LPS IgA responses steadily declined, being 254 
significantly higher at day 11 and day 18, but returning to a level which was comparable with baseline 255 
at 1.5 years. In humans, memory B-cells can essentially persist for the life of the host (more than 50 256 
years); however, typically, levels of circulating immunoglobulin decline rapidly following clearance of 257 
the antigen [29-31]. Thus, if the antigen is not reencountered in vivo, immunoglobulin responses are 258 
unlikely to be detected in the long-term. 259 
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The assessment of baseline immunoglobulin levels indicates that groups were well matched for prior 260 
exposure to S. Typhi. We have previously observed that heterologous influenza-responsive T-cell 261 
responses are generated at the duodenal mucosa 18 days following vaccination with Ty21a. 262 
Unfortunately, we were unable to determine the longevity of these responses in this study as the 263 
majority of the vaccinated cohort had been vaccinated against influenza in the period since being 264 
vaccinated with Ty21a (data not shown). We assessed the expression of four cytokines and one 265 
chemokine, as a result, the T-cell populations identified here are unlikely to represent the responsive 266 
populations in their entirety. While we have focused on the assessment of mucosal cellular immune 267 
defence, further studies which analyse interplay between cellular and humoral immune defence at 268 
the intestinal mucosa would provide us with a more comprehensive overview of the human immune 269 
response to vaccination. The use of intestinal lavage has been used in other studies to quantify IgA in 270 
mucosal secretions [32]. Variation within the human population may mean that we are underpowered 271 
to observe some other important biological effects. 272 
Taken together, our data demonstrate that early intestinal responses do not persist locally at the 273 
duodenal mucosa in the long-term. The fact that oral vaccination does generate peripheral 274 
populations which persist for at least 1.5 years supports the development of next-generation oral 275 
vaccines targeting typhoid, since it demonstrates longevity of orally induced cellular responses. Data 276 
presented elsewhere indicate that populations generated through oral vaccination express the 277 
homing molecules necessary to rapidly migrate to the intestinal mucosa following pathogenic 278 
exposure [25]. Controlled human infection, post-vaccination, may allow us to identify mechanisms 279 
responsible for efficacious defence against pathogens encountered at the intestinal mucosa and in the 280 
peripheral circulation.  281 
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Table 1. Volunteer demographics, vaccination and sampling information 372 
Study Group Study Number Gender Age Time from Vaccination to Sampling Years Median (Years) 
Vaccine 
4539/02 F 20 1.6 
1.5 
4539/03 F 18 1.4 
4539/05 F 30 1.4 
4539/07 F 20 1.1 
4539/09 F 26 1.5 
4539/12 M 21 1.6 
4539/13 M 22 1.5 
4539/14 M 37 3.7 
Control 
4539/01 F 22 
N/A N/A 
4539/04 F 22 
4539/08 F 26 
4539/10 F 23 
4539/11 M 24 
4539/15 F 26 
4539/16 M 25 
4539/17 M 23 
4539/18 M 35 
4539/19 M 20 
 373 
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 375 
Figure 1. Levels of serum immunoglobulin (Ig)G and IgA to Salmonella Typhi lipopolysaccharide 376 
(LPS). The levels of IgG and IgA specific to Salmonella Typhi LPS in serum, expressed in arbitrary units 377 
(AU). Unpaired comparisons were made between control (C; closed squares) and vaccinated (V; open 378 
squares) volunteers at baseline (unpaired t tests were performed using logarithmically transformed 379 
data). Paired comparisons were made between baseline (T0) and day 11 (T1), day 18 (T2) and 380 
approximately 1.5 years (T3) (paired t tests were performed using logarithmically transformed data). 381 
Horizontal bars represent mean values. Abbreviation: ns, not significant; *, bootstrapped 95% 382 
confidence interval does not cross 0. 383 
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 385 
Figure 2. Representative flow cytometric gating strategy for intracellular cytokine analysis. Dot plots 386 
are shown for cells isolated from (A) peripheral blood and (B) the duodenal mucosa. Dead cells were 387 
removed by staining for viability (LIVE/DEAD) and gating on the negative population. T cells were 388 
identified according to the expression of CD3. T cells were classified according to the expression of 389 
CD4 and CD8 and the expression of IFN-γ, TNF-α, IL-2, IL-17A, and MIP-1β assessed in non-stimulated 390 
(NS) and in Ty21a, FliC and SEB stimulated samples. Values were expressed as the percentage of the 391 
parent CD4+ or CD8+ population. 392 
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 394 
Figure 3. Antigen-specific cytokine-producing populations at 1.5 years. The frequency of CD4+ and 395 
CD8+ Salmonella Typhi strain Ty21a-responsive and FliC-responsive populations expressing any 396 
combination of IFN-γ ± TNF-α ± IL-2 ± IL-17A ± MIP-1β above background. SEB-stimulated control data 397 
are also included. For control (C; closed squares, diamonds and triangles) and vaccinated (V; open 398 
squares, diamonds and triangles) volunteers, measurements were made at the duodenal mucosa (A), 399 
and in peripheral blood (B). Values are expressed as the percentage of the parent CD4+ or CD8+ 400 
population. Horizontal bars represent mean values. Abbreviation: ns, not significant; *, bootstrapped 401 
95% confidence interval does not cross 0. 402 
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 404 
Figure 4. Combinations of antigen-specific cytokine production in peripheral blood. The frequency 405 
of CD4+ and CD8+ Ty21a-responsive (A and B) and FliC-responsive (C and D) populations expressing one 406 
(+), or polyfunctional populations expressing two (++), three (+++), four (++++) or five (+++++) 407 
cytokines/chemokines (IFN-γ ± TNF-α ± IL-2 ± IL1-7 ± MIP-1β) above background. For control (C; closed 408 
squares and diamonds) and vaccinated (V; open squares and diamonds) volunteers. Values are 409 
expressed as the percentage of the parent CD4+ or CD8+ population. Horizontal bars represent mean 410 
values. Abbreviation: ns, not significant; *, bootstrapped 95% confidence interval does not cross 0. 411 
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 413 
Figure 5. Antigen-specific production of individual cytokines in peripheral blood. The frequency of 414 
CD4+ and CD8+ Ty21a-responsive (A and B) and FliC-responsive (C and D) populations expressing IFN-415 
γ, TNF-α, IL-2, IL-17A, or MIP-1β above background. For control (C; closed squares and diamonds) and 416 
vaccinated (V; open squares and diamonds) volunteers. Values are expressed as the percentage of the 417 
parent CD4+ or CD8+ population. Horizontal bars represent mean values. 418 
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 420 
Supplementary Figure 1. Combinations of antigen-specific cytokine production at the duodenal 421 
mucosa. The frequency of CD4+ and CD8+ Salmonella Typhi strain Ty21a-responsive (A and B) and FliC-422 
responsive (C and D) populations expressing one (+), or polyfunctional populations expressing two 423 
(++), three (+++), four (++++) or five (+++++) cytokines/chemokines (IFN-γ ± TNF-α ± IL-2 ± IL-17A ± 424 
MIP-1β) above background. For control (C; closed squares and diamonds) and vaccinated (V; open 425 
squares and diamonds) volunteers. Values are expressed as the percentage of the parent CD4+ or CD8+ 426 
population. Horizontal bars represent mean values. Abbreviation: ns, not significant; *, bootstrapped 427 
95% confidence interval does not cross 0. 428 
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Supplementary Figure 2. Antigen-specific production of individual cytokines at the duodenal 431 
mucosa. The frequency of CD4+ and CD8+ Ty21a-responsive (A and B) and FliC-responsive (C and D) 432 
populations expressing IFN-γ, TNF-α, IL-2, IL-17A, or MIP-1β above background. For control (C; closed 433 
squares and diamonds) and vaccinated (V; open squares and diamonds) volunteers. Values are 434 
expressed as the percentage of the parent CD4+ or CD8+ population. Horizontal bars represent mean 435 
values. 436 
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